<DOC>
	<DOCNO>NCT00043966</DOCNO>
	<brief_summary>The purpose study compare safety , tolerability antiviral activity once-daily ( QD ) twice-daily ( BID ) dose lopinavir/ritonavir characterize pharmacokinetics once-daily dose lopinavir/ritonavir .</brief_summary>
	<brief_title>Study Lopinavir , Ritonavir , Tenofovir Emtricitabine HIV-Infected Antiretroviral Naïve Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Subject least 18 year age . If female , subject childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential practice one follow method birth control : *condoms , sponge , foam , jelly , diaphragm intrauterine device ( IUD ) *contraceptives ( oral parenteral ) three month prior study drug administration ) *a vasectomized partner *total abstinence sexual intercourse If female , result urine pregnancy test perform screening ( urine specimen obtain earlier 28 day prior study drug administration ) urine pregnancy test perform Study Day 1 negative subject agree use barrier method contraception throughout study . Subject breastfeeding . Vital sign , physical examination laboratory result exhibit evidence acute illness . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic , endocrinologic , metabolic hepatic disease would adversely affect his/her participate study . Subject require agrees take follow medication duration study : midazolam , triazolam , terfenadine , astemizole , cisapride , pimozide , propafenone , flecainide , certain ergot derivative ( ergotamine , dihydroergotamine , ergonovine , methylergonovine ) , rifampin , lovastatin , simvastatin , St. John ’ wort . Subject agrees take medication study , include overthecounter medicine , herbal medication , alcohol recreational drug without knowledge permission principal investigator . Subject Karnofsky Score great equal 70 Subject treat active AIDSdefining opportunistic infection within 30 day screen . Subjects stable maintenance therapy opportunistic infection may enrol consultation Abbott . Subject naive antiretroviral treatment ( &lt; 7 day ARV treatment ) . Subject plasma HIV RNA level great 1,000 copies/mL screening . Subject agrees take dos lopinavir/ritonavir bottle provide sponsor ( rather take dos personal “ dosette ” box ) . Subject voluntarily sign date informed consent form , approve Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) , nature study explain subject opportunity ask question . The informed consent must sign studyspecific procedure perform . Subject history allergic reaction significant sensitivity lopinavir/ritonavir , tenofovir emtricitabine drug similar study drug . Subject recent ( within past 6 month ) history drug and/or alcohol abuse . Subject positive result screen test drug abuse . Subject history substance abuse psychiatric illness could preclude adherence protocol . Screening laboratory analysis show follow abnormal laboratory result : *Hemoglobin ≤ 8.0 g/dL *Absolute neutrophil count ≤ 750 cells/µL *Platelet count ≤ 50,000 per mL *ALT AST ≥ 3.0 x Upper Limit Normal ( ULN ) *Creatinine ≥ 1.5 x Upper Limit Normal ( ULN ) Subject receive investigational drug within 30 day prior study drug administration . For reason , subject consider investigator unsuitable candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>treatment naive</keyword>
</DOC>